Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2018
Geographically, this report split Europe into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Pulmonary Arterial Hypertension (PAH) Drugs for these regions, from 2012 to 2023 (forecast), including Germany UK
Geographically, this report split Europe into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Pulmonary Arterial Hypertension (PAH) Drugs for these regions, from 2012 to 2023 (forecast), including
Germany
UK
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Report</strong> Title:<br />
<strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>)<br />
<strong>Drugs</strong> <strong>Market</strong> <strong>Report</strong> <strong>2018</strong><br />
Published On: May <strong>2018</strong><br />
Pages: 113<br />
Category: Life Sciences<br />
<strong>Report</strong> Overview:<br />
Geographically, this report split <strong>Europe</strong> into several key Regions, with sales (K Units),<br />
revenue (Million USD), market share and growth rate of <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong><br />
(<strong>PAH</strong>) <strong>Drugs</strong> for these regions, from 2012 to 2023 (forecast), including<br />
Germany<br />
UK<br />
France<br />
Russia<br />
Benelux<br />
Italy<br />
Spain<br />
<strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> market competition by top<br />
manufacturers/players, with <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> sales volume,<br />
price, revenue (Million USD) and market share for each manufacturer/player; the top players<br />
including<br />
Actelion Pharmaceuticals<br />
DAIICHI SANKYO<br />
GlaxoSmithKline<br />
Novartis<br />
United Therapeutics<br />
AADi<br />
Actelion Pharmaceuticals<br />
Aires Pharmaceuticals<br />
Arena Pharmaceuticals<br />
Asklepion Pharmaceuticals<br />
AstraZeneca<br />
Bayer Healthcare<br />
Berlin Cures<br />
BIAL<br />
24marketreports | International +1 646 781 7170 | www.24marketreports.com
Eiger BioPharmaceuticals<br />
On the basis of product, this report displays the sales volume (K Units), revenue (Million<br />
USD), product price (USD/Unit), market share and growth rate of each type, primarily split<br />
into<br />
Inhalation<br />
Injectables<br />
Oral administration<br />
On the basis on the end users/applications, this report focuses on the status and outlook for<br />
major applications/end users, sales volume (K Units), market share and growth rate of<br />
<strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> for each application, including<br />
ERAs<br />
Prostacyclin analogs<br />
PDE inhibitors<br />
sGC stimulators<br />
If you have any special requirements, please let us know and we will offer you the report as<br />
you want.<br />
Table of Contents:<br />
Table of Contents<br />
<strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> <strong>Market</strong> <strong>Report</strong> 2012-2023<br />
1 <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Overview<br />
1.1 Product Overview and Scope of <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong><br />
1.2 Classification of <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> by Product Category<br />
1.2.1 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) Comparison by<br />
Types (2012-2023)<br />
1.2.2 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) <strong>Market</strong> Share by<br />
Types in 2017<br />
1.2.3 Inhalation<br />
1.2.4 Injectables<br />
1.2.5 Oral administration<br />
1.3 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> <strong>Market</strong> by Application/End Users<br />
1.3.1 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> (K Units) and <strong>Market</strong> Share<br />
Comparison by Applications (2012-2023)<br />
1.3.2 ERAs<br />
1.3.3 Prostacyclin analogs<br />
1.3.4 PDE inhibitors<br />
1.3.5 sGC stimulators<br />
24marketreports | International +1 646 781 7170 | www.24marketreports.com
1.4 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> <strong>Market</strong> by Region<br />
1.4.1 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Revenue (Million USD)<br />
Comparison by Regions (2012-2023)<br />
1.4.2 Germany Status and Prospect (2012-2023)<br />
1.4.3 UK Status and Prospect (2012-2023)<br />
1.4.4 France Status and Prospect (2012-2023)<br />
1.4.5 Russia Status and Prospect (2012-2023)<br />
1.4.6 Benelux Status and Prospect (2012-2023)<br />
1.4.7 Italy Status and Prospect (2012-2023)<br />
1.4.8 Spain Status and Prospect (2012-2023)<br />
1.5 <strong>Europe</strong> Sales and Revenue ofSales and Revenue of <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>)<br />
<strong>Drugs</strong> (2012-2023)<br />
1.5.1 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and Growth Rate<br />
(2012-2023)<br />
1.5.2 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Revenue (Million USD) and<br />
Growth Rate (2012-2023)<br />
2 Industrial Chain Analysis<br />
2.1 Industry Chain Structure of <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong><br />
2.2 Raw Material Analysis of <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong><br />
2.1.1 Raw Material A <strong>Market</strong> Analysis<br />
2.1.2 Raw Material B <strong>Market</strong> Analysis<br />
2.1.3 Raw Material C <strong>Market</strong> Analysis<br />
2.3 Labor Cost Analysis of <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong><br />
2.4 Other Costs Analysis of <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong><br />
2.5 Manufacturing Cost Structure Analysis of <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong><br />
2.6 Manufacturing Process Analysis of <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong><br />
2.7 Raw Materials Sources of <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Major<br />
Manufacturers in <strong>2018</strong><br />
2.8 Downstream Buyers<br />
3 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Players/Suppliers Profiles and Sales<br />
Data<br />
3.1 Actelion Pharmaceuticals<br />
3.1.1 Company Basic Information, Manufacturing Base and Competitors<br />
3.1.2 <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Product Category, Application and<br />
Specification<br />
3.1.2.1 Product A<br />
3.1.2.2 Product B<br />
3.1.3 Actelion Pharmaceuticals <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units),<br />
Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)<br />
3.1.4 Actelion Pharmaceuticals Different Types of <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>)<br />
<strong>Drugs</strong> Sales (K Units), Revenue (Million USD) and Price (USD/Unit) (2012-2017)<br />
3.1.5 Actelion Pharmaceuticals <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Volume in<br />
Different Applications and Its Application Share<br />
3.2 DAIICHI SANKYO<br />
24marketreports | International +1 646 781 7170 | www.24marketreports.com
3.2.1 Company Basic Information, Manufacturing Base and Competitors<br />
3.2.2 <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Product Category, Application and<br />
Specification<br />
3.2.2.1 Product A<br />
3.2.2.2 Product B<br />
3.2.3 DAIICHI SANKYO <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units),<br />
Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)<br />
3.2.4 DAIICHI SANKYO Different Types of <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales<br />
(K Units), Revenue (Million USD) and Price (USD/Unit) (2012-2017)<br />
3.2.5 DAIICHI SANKYO <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Volume in Different<br />
Applications and Its Application Share<br />
3.3 GlaxoSmithKline<br />
3.3.1 Company Basic Information, Manufacturing Base and Competitors<br />
3.3.2 <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Product Category, Application and<br />
Specification<br />
3.3.2.1 Product A<br />
3.3.2.2 Product B<br />
3.3.3 GlaxoSmithKline <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units), Revenue<br />
(Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)<br />
3.3.4 GlaxoSmithKline Different Types of <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales<br />
(K Units), Revenue (Million USD) and Price (USD/Unit) (2012-2017)<br />
3.3.5 GlaxoSmithKline <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Volume in Different<br />
Applications and Its Application Share<br />
3.4 Novartis<br />
3.4.1 Company Basic Information, Manufacturing Base and Competitors<br />
3.4.2 <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Product Category, Application and<br />
Specification<br />
3.4.2.1 Product A<br />
3.4.2.2 Product B<br />
3.4.3 Novartis <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units), Revenue (Million<br />
USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)<br />
3.4.4 Novartis Different Types of <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K<br />
Units), Revenue (Million USD) and Price (USD/Unit) (2012-2017)<br />
3.4.5 Novartis <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Volume in Different Applications<br />
and Its Application Share<br />
3.5 United Therapeutics<br />
3.5.1 Company Basic Information, Manufacturing Base and Competitors<br />
3.5.2 <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Product Category, Application and<br />
Specification<br />
3.5.2.1 Product A<br />
3.5.2.2 Product B<br />
3.5.3 United Therapeutics <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units),<br />
Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)<br />
3.5.4 United Therapeutics Different Types of <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong><br />
Sales (K Units), Revenue (Million USD) and Price (USD/Unit) (2012-2017)<br />
3.5.5 United Therapeutics <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Volume in Different<br />
24marketreports | International +1 646 781 7170 | www.24marketreports.com
Applications and Its Application Share<br />
3.6 AADi<br />
3.6.1 Company Basic Information, Manufacturing Base and Competitors<br />
3.6.2 <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Product Category, Application and<br />
Specification<br />
3.6.2.1 Product A<br />
3.6.2.2 Product B<br />
3.6.3 AADi <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units), Revenue (Million<br />
USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)<br />
3.6.4 AADi Different Types of <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units),<br />
Revenue (Million USD) and Price (USD/Unit) (2012-2017)<br />
3.6.5 AADi <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Volume in Different Applications and<br />
Its Application Share<br />
3.7 Actelion Pharmaceuticals<br />
3.7.1 Company Basic Information, Manufacturing Base and Competitors<br />
3.7.2 <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Product Category, Application and<br />
Specification<br />
3.7.2.1 Product A<br />
3.7.2.2 Product B<br />
3.7.3 Actelion Pharmaceuticals <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units),<br />
Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)<br />
3.7.4 Actelion Pharmaceuticals Different Types of <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>)<br />
<strong>Drugs</strong> Sales (K Units), Revenue (Million USD) and Price (USD/Unit) (2012-2017)<br />
3.7.5 Actelion Pharmaceuticals <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Volume in<br />
Different Applications and Its Application Share<br />
3.8 Aires Pharmaceuticals<br />
3.8.1 Company Basic Information, Manufacturing Base and Competitors<br />
3.8.2 <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Product Category, Application and<br />
Specification<br />
3.8.2.1 Product A<br />
3.8.2.2 Product B<br />
3.8.3 Aires Pharmaceuticals <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units),<br />
Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)<br />
3.8.4 Aires Pharmaceuticals Different Types of <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong><br />
Sales (K Units), Revenue (Million USD) and Price (USD/Unit) (2012-2017)<br />
3.8.5 Aires Pharmaceuticals <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Volume in Different<br />
Applications and Its Application Share<br />
3.9 Arena Pharmaceuticals<br />
3.9.1 Company Basic Information, Manufacturing Base and Competitors<br />
3.9.2 <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Product Category, Application and<br />
Specification<br />
3.9.2.1 Product A<br />
3.9.2.2 Product B<br />
3.9.3 Arena Pharmaceuticals <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units),<br />
Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)<br />
3.9.4 Arena Pharmaceuticals Different Types of <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong><br />
24marketreports | International +1 646 781 7170 | www.24marketreports.com
Sales (K Units), Revenue (Million USD) and Price (USD/Unit) (2012-2017)<br />
3.9.5 Arena Pharmaceuticals <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Volume in<br />
Different Applications and Its Application Share<br />
3.10 Asklepion Pharmaceuticals<br />
3.10.1 Company Basic Information, Manufacturing Base and Competitors<br />
3.10.2 <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Product Category, Application and<br />
Specification<br />
3.10.2.1 Product A<br />
3.10.2.2 Product B<br />
3.10.3 Asklepion Pharmaceuticals <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K<br />
Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (%) (2012-2017)<br />
3.10.4 Asklepion Pharmaceuticals Different Types of <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>)<br />
<strong>Drugs</strong> Sales (K Units), Revenue (Million USD) and Price (USD/Unit) (2012-2017)<br />
3.10.5 Asklepion Pharmaceuticals <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Volume in<br />
Different Applications and Its Application Share<br />
3.11 AstraZeneca<br />
3.12 Bayer Healthcare<br />
3.13 Berlin Cures<br />
3.14 BIAL<br />
3.15 Eiger BioPharmaceuticals<br />
4 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Competition by<br />
Players/Manufacturers, Region, Type and Application<br />
4.1 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> <strong>Market</strong> Competition by<br />
Players/Manufacturers<br />
4.1.1 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and <strong>Market</strong> Share<br />
of Key Players/Suppliers (2012-2017)<br />
4.1.2 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Revenue (Million USD) and Share<br />
by Players/Suppliers (2012-2017)<br />
4.2 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales and Revenue by Type<br />
4.2.1 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and <strong>Market</strong> Share<br />
by Type (2012-2017)<br />
4.2.2 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Revenue (Million USD) and<br />
<strong>Market</strong> Share by Type (2012-2017)<br />
4.3 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales and Revenue by Application<br />
4.3.1 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and <strong>Market</strong> Share<br />
by Regions (2012-2017)<br />
4.3.2 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Revenue (Million USD) and<br />
<strong>Market</strong> Share (%) Regions (2012-2017)<br />
4.4 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) by Application<br />
5 Germany <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> (Sales, Revenue and Price)<br />
5.1 Germany <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales and Value (2012-2017)<br />
5.1.1 Germany <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and Growth Rate<br />
(2012-2017)<br />
5.1.2 Germany <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Revenue and Growth Rate<br />
24marketreports | International +1 646 781 7170 | www.24marketreports.com
(2012-2017)<br />
5.1.3 Germany <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales Price (USD/Unit) Trend<br />
(2012-2017)<br />
5.2 Germany <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and <strong>Market</strong> Share<br />
by Type<br />
5.3 Germany <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and <strong>Market</strong> Share<br />
by Application<br />
6 UK <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> (Sales, Revenue and Price)<br />
6.1 UK <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales and Value (2012-2017)<br />
6.1.1 UK <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and Growth Rate<br />
(2012-2017)<br />
6.1.2 UK <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Revenue and Growth Rate (2012-2017)<br />
6.1.3 UK <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales Price (USD/Unit) Trend<br />
(2012-2017)<br />
6.2 UK <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and <strong>Market</strong> Share by<br />
Type<br />
6.3 UK <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and <strong>Market</strong> Share by<br />
Application<br />
7 France <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> (Sales, Revenue and Price)<br />
7.1 France <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales and Value (2012-2017)<br />
7.1.1 France <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and Growth Rate<br />
(2012-2017)<br />
7.1.2 France <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Revenue and Growth Rate<br />
(2012-2017)<br />
7.1.3 France <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales Price (USD/Unit) Trend<br />
(2012-2017)<br />
7.2 France <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and <strong>Market</strong> Share by<br />
Type<br />
7.3 France <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and <strong>Market</strong> Share by<br />
Application<br />
8 Russia <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> (Sales, Revenue and Price)<br />
8.1 Russia <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales and Value (2012-2017)<br />
8.1.1 Russia <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and Growth Rate<br />
(2012-2017)<br />
8.1.2 Russia <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Revenue and Growth Rate<br />
(2012-2017)<br />
8.1.3 Russia <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales Price (USD/Unit) Trend<br />
(2012-2017)<br />
8.2 Russia <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and <strong>Market</strong> Share by<br />
Type<br />
8.3 Russia <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and <strong>Market</strong> Share by<br />
Application<br />
24marketreports | International +1 646 781 7170 | www.24marketreports.com
9 Benelux <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> (Sales, Revenue and Price)<br />
9.1 Benelux <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales and Value (2012-2017)<br />
9.1.1 Benelux <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and Growth Rate<br />
(2012-2017)<br />
9.1.2 Benelux <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Revenue and Growth Rate<br />
(2012-2017)<br />
9.1.3 Benelux <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales Price (USD/Unit) Trend<br />
(2012-2017)<br />
9.2 Benelux <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and <strong>Market</strong> Share<br />
by Type<br />
9.3 Benelux <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and <strong>Market</strong> Share<br />
by Application<br />
10 Italy <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> (Sales, Revenue and Price)<br />
10.1 Italy <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales and Value (2012-2017)<br />
10.1.1 Italy <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and Growth Rate<br />
(2012-2017)<br />
10.1.2 Italy <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Revenue and Growth Rate<br />
(2012-2017)<br />
10.1.3 Italy <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales Price (USD/Unit) Trend<br />
(2012-2017)<br />
10.2 Italy <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and <strong>Market</strong> Share by<br />
Type<br />
10.3 Italy <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and <strong>Market</strong> Share by<br />
Application<br />
11 Spain <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> (Sales, Revenue and Price)<br />
11.1 Spain <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales and Value (2012-2017)<br />
11.1.1 Spain <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and Growth Rate<br />
(2012-2017)<br />
11.1.2 Spain <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Revenue and Growth Rate<br />
(2012-2017)<br />
11.1.3 Spain <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales Price (USD/Unit) Trend<br />
(2012-2017)<br />
11.2 Spain <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and <strong>Market</strong> Share by<br />
Type<br />
11.3 Spain <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and <strong>Market</strong> Share by<br />
Application<br />
12 <strong>Market</strong>ing Strategy Analysis, Distributors/Traders<br />
12.1 Direct <strong>Market</strong>ing<br />
12.1.1 Direct <strong>Market</strong>ing<br />
12.1.2 Indirect <strong>Market</strong>ing<br />
12.1.3 <strong>Market</strong>ing Channel Development Trend<br />
12.2 <strong>Market</strong> Positioning<br />
12.2.1 Pricing Strategy<br />
24marketreports | International +1 646 781 7170 | www.24marketreports.com
12.2.2 Brand Strategy<br />
12.2.3 Target Client<br />
12.3 Distributors/Traders List<br />
13 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> <strong>Market</strong> Forecast (<strong>2018</strong>-2023)<br />
13.1 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units), Revenue and Price<br />
Forecast (<strong>2018</strong>-2023)<br />
13.1.1 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and Growth Rate<br />
Forecast (<strong>2018</strong>-2023)<br />
13.1.2 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Revenue and Growth Rate<br />
Forecast (<strong>2018</strong>-2023)<br />
13.1.3 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Price and Trend Forecast<br />
(<strong>2018</strong>-2023)<br />
13.2 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units), Revenue and<br />
Growth Rate Forecast by Region (<strong>2018</strong>-2023)<br />
13.2.1 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales (K Units) and Growth Rate<br />
Forecast by Region (<strong>2018</strong>-2023)<br />
13.2.2 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Revenue and Growth Rate<br />
Forecast by Region (<strong>2018</strong>-2023)<br />
13.2.3 Germany <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales, Revenue and Growth<br />
Rate Forecast (<strong>2018</strong>-2023)<br />
13.2.4 UK <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales, Revenue and Growth Rate<br />
Forecast (<strong>2018</strong>-2023)<br />
13.2.5 France <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales, Revenue and Growth Rate<br />
Forecast (<strong>2018</strong>-2023)<br />
13.2.6 Russia <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales, Revenue and Growth Rate<br />
Forecast (<strong>2018</strong>-2023)<br />
13.2.7 France <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales, Revenue and Growth Rate<br />
Forecast (<strong>2018</strong>-2023)<br />
13.2.8 Italy <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales, Revenue and Growth Rate<br />
Forecast (<strong>2018</strong>-2023)<br />
13.2.9 Spain <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales, Revenue and Growth Rate<br />
Forecast (<strong>2018</strong>-2023)<br />
13.3 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales, Revenue and Price Forecast<br />
by Type (<strong>2018</strong>-2023)<br />
13.3.1 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales Forecast by Type<br />
(<strong>2018</strong>-2023)<br />
13.3.2 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Revenue Forecast by Type<br />
(<strong>2018</strong>-2023)<br />
13.3.3 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Price Forecast by Type<br />
(<strong>2018</strong>-2023)<br />
13.4 <strong>Europe</strong> <strong>Pulmonary</strong> <strong>Arterial</strong> <strong>Hypertension</strong> (<strong>PAH</strong>) <strong>Drugs</strong> Sales Forecast by Application<br />
(<strong>2018</strong>-2023)<br />
14 Research Findings and Conclusion<br />
24marketreports | International +1 646 781 7170 | www.24marketreports.com
15 Appendix<br />
15.1 Methodology/Research Approach<br />
15.1.1 Research Programs/Design<br />
15.1.2 <strong>Market</strong> Size Estimation<br />
15.1.3 <strong>Market</strong> Breakdown and Data Triangulation<br />
15.2 Data Source<br />
15.2.1 Secondary Sources<br />
15.2.2 Primary Sources<br />
15.3 Disclaimer<br />
Get More Information about the <strong>Report</strong>:<br />
<strong>Report</strong> URL:<br />
https://www.24marketreports.com/life-sciences/europe-pulmonary-arterial-hypertension-pah-dr<br />
ugs-market-report-<strong>2018</strong><br />
To get <strong>Report</strong> Sample:<br />
https://www.24marketreports.com/request-sample/europe-pulmonary-arterial-hypertension-pah<br />
-drugs-market-report-<strong>2018</strong><br />
24marketreports | International +1 646 781 7170 | www.24marketreports.com
Change language